Diller Ricarda, Sonntag Anne K, Mellmann Alexander, Grevener Knut, Senninger Norbert, Kipp Frank, Friedrich Alexander W
Department of General Surgery, University Hospital of Münster, Waldeyerstrasse 1, 48149 Münster, Germany.
Int J Hyg Environ Health. 2008 Mar;211(1-2):205-12. doi: 10.1016/j.ijheh.2007.06.001. Epub 2007 Aug 9.
Colonization with methicillin-resistant Staphylococcus aureus (MRSA) is a risk factor for MRSA infection causing increased costs in patient's care and treatment. To evaluate cost efficiency, pre-admission MRSA screening and subsequent MRSA decolonization of patients admitted to the Department of General Surgery at the University Hospital of Münster were determined. In 2004, 2054 (89.3%) out of the total of 2299 hospital-admitted patients were screened for MRSA (1769 elective and 530 direct admissions); 1536 patients underwent pre-admission MRSA screening (86.8% of the 1769 elective admissions), of whom seven patients (0.5%) were MRSA-positive and five of these were successfully decolonized before admission. In case of direct admissions, i.e., emergency cases or transferral from other hospitals, 2.4% and 8.6% were MRSA-positive, respectively. There were 25 patients MRSA positive during their hospital stay, two of these were nosocomially acquired, which represent 0.1 nosocomial MRSA cases in 1000 in-patients. The average MRSA carrier was (65+/-15 years) older than the other patients (55+/-17 years), had a significantly higher rate of pulmonary disease, coronary heart disease and certain infections; and had a longer hospital stay (27 versus 10 days, p<0.05). The total costs of the MRSA screening were approximately 20,000 euro. Since the estimated costs for handling MRSA treatment and isolation during a hospital stay are 6000-10,000 euro for each affected patient, we estimated that approximately 20,000 euro could be saved by detecting and successfully decolonizing a total of five patients through pre-admission screening. In this calculation, additional costs due to the increased morbidity and mortality of MRSA carriers and the possible spread of MRSA through unrecognized colonization were not included. In conclusion, pre-admission screening for MRSA is an effective method to reduce the hospital burden of MRSA-colonized patients and the savings due to consistent decolonization before elective admission outweigh the costs of screening.
耐甲氧西林金黄色葡萄球菌(MRSA)定植是导致MRSA感染的一个风险因素,会增加患者护理和治疗成本。为评估成本效益,对明斯特大学医院普通外科收治患者进行了入院前MRSA筛查及后续MRSA去定植治疗。2004年,在2299名入院患者中,2054名(89.3%)接受了MRSA筛查(1769名择期入院患者和530名直接入院患者);1536名患者接受了入院前MRSA筛查(占1769名择期入院患者的86.8%),其中7名患者(0.5%)MRSA检测呈阳性,其中5名在入院前成功去定植。对于直接入院患者,即急诊病例或从其他医院转来的患者,MRSA阳性率分别为2.4%和8.6%。住院期间有25名患者MRSA检测呈阳性,其中2名是医院获得性感染,即每1000名住院患者中有0.1例医院获得性MRSA病例。MRSA携带者的平均年龄(65±15岁)高于其他患者(55±17岁),肺部疾病、冠心病和某些感染的发生率显著更高;住院时间更长(分别为27天和10天,p<0.05)。MRSA筛查的总成本约为20000欧元。由于预计每位受影响患者住院期间处理MRSA治疗和隔离的成本为6000 - 10000欧元,我们估计通过入院前筛查总共检测出并成功去定植5名患者可节省约20000欧元。在此计算中,未包括MRSA携带者发病率和死亡率增加以及MRSA通过未识别的定植可能传播所产生的额外成本。总之,入院前MRSA筛查是减轻MRSA定植患者医院负担的有效方法,择期入院前持续去定植所节省的费用超过筛查成本。